Clinical Trial Update: Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age [Phase 4]

View source ↗

Summary

Phase 4 trial update reporting safety, tolerability, and immunogenicity data for the Meningococcal C Conjugate Vaccine in children aged 32 to 40 months. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal C Conjugate Vaccine (Meningococcal C conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Meningococcal Infection | Phase 4 | Status: COMPLETED